Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?

被引：51

作者：

van Heeckeren, WJ ^{[1
]}

Bhakta, S

Ortiz, J

Duerk, J

Cooney, MM

Dowlati, A

McCrae, K

Remick, SC

机构：

[1] Case Western Reserve Univ, Sch Med, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA

[2] CASE Sch Med, Dept Med, Div Cardiol, Cleveland, OH USA

[3] CASE Sch Med, Dept Radiol, Cleveland, OH USA

[4] CASE Sch Med, Dept Biomed Engn, Cleveland, OH USA

[5] Univ Hosp Cleveland, CASE Comprehens Canc Ctr, Dev Therapeut Program, Cleveland, OH 44106 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 10期

关键词：

D O I：

10.1200/JCO.2005.04.8801

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1485 / 1488

页数：4

共 27 条

[1] Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].

Beaudry, P ;

Force, J ;

Naumov, GN ;

Wang, A ;

Baker, CH ;

Ryan, A ;

Soker, S ;

Johnson, BE ;

Folkman, J ;

Heymach, JV .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3514-3522

[2] Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [J].

Beerepoot, LV ;

Radema, SA ;

Witteveen, EO ;

Thomas, T ;

Wheeler, C ;

Kempin, S ;

Voest, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) :1491-1498

[3] Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve [J].

Celik, I ;

Sürfücü, O ;

Dietz, C ;

Heymach, JV ;

Force, J ;

Höschele, I ;

Becker, CM ;

Folkman, J ;

Kisker, O .

CANCER RESEARCH, 2005, 65 (23) :11044-11050

[4]

Cooney M, 2004, CLIN CANCER RES, V10, P5968

[5] Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds [J].

Cooney M.M. ;

Ortiz J. ;

Bukowski R.M. ;

Remick S.C. .

Current Oncology Reports, 2005, 7 (2) :90-95

[6] Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer [J].

Cooney, MM ;

Radivoyevitch, T ;

Dowlati, A ;

Overmoyer, B ;

Levitan, N ;

Robertson, K ;

Levine, SL ;

DeCaro, K ;

Buchter, C ;

Taylor, A ;

Stambler, BS ;

Remick, SC .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :96-100

[7]

DELPROPOSTO Z, 2002, P AN M AM SOC CLIN, V20, pA111

[8] Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease - A TACTICS-TIMI-18 substudy [J].

Dokainish, H ;

Pillai, M ;

Murphy, SA ;

DiBattiste, PM ;

Schweiger, MJ ;

Lotfi, A ;

Morrow, DA ;

Cannon, CP ;

Braunwald, E ;

Lakkis, N .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (01) :19-24

[9]

Dowlati A, 2002, CANCER RES, V62, P3408

[10] Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 [J].

Evelhoch, JL ;

LoRusso, PM ;

He, ZQ ;

DelProposto, Z ;

Polin, L ;

Corbett, TH ;

Langmuir, P ;

Wheeler, C ;

Stone, A ;

Leadbetter, J ;

Ryan, AJ ;

Blakey, DC ;

Waterton, JC .

CLINICAL CANCER RESEARCH, 2004, 10 (11) :3650-3657

← 1 2 3 →